BR0011296A - Derivados de espiroimidazolidina, preparação dos mesmos, utilização dos mesmos e preparações farmacêuticas compreendendo os mesmos - Google Patents

Derivados de espiroimidazolidina, preparação dos mesmos, utilização dos mesmos e preparações farmacêuticas compreendendo os mesmos

Info

Publication number
BR0011296A
BR0011296A BR0011296-8A BR0011296A BR0011296A BR 0011296 A BR0011296 A BR 0011296A BR 0011296 A BR0011296 A BR 0011296A BR 0011296 A BR0011296 A BR 0011296A
Authority
BR
Brazil
Prior art keywords
formula
compounds
same
preparation
pharmaceutical preparations
Prior art date
Application number
BR0011296-8A
Other languages
English (en)
Other versions
BR0011296B1 (pt
Inventor
Volkmar Wehner
Hans Ulrich Stilz
Wolfgang Schmidt
Dirk Seiffge
Original Assignee
Aventis Pharma Deustschland Gm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deustschland Gm filed Critical Aventis Pharma Deustschland Gm
Publication of BR0011296A publication Critical patent/BR0011296A/pt
Publication of BR0011296B1 publication Critical patent/BR0011296B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção: "DERIVADOS DE ESPIROIMIDAZOLIDINA, PREPARAçãO DOS MESMOS, UTILIZAçãO DOS MESMOS E PREPARAçõES FARMACêUTICAS COMPREENDENDO OS MESMOS". A presente invenção refere-se a derivados da espiroimidazolidina da fórmula (I) em que E, V, W, X, R^ 1^ e R^ 2^ possuem os significados indicados nas reivindicações. Os compostos da fórmula (I) são compostos farmacêuticos ativos de valor que são adequados, por exemplo, para a terapia e a profilaxia de distúrbios inflamatórios, por exemplo de artrite reumatóide ou de distúrbios alérgicos. Os compostos da fórmula (I) são inibidores da adesão e da migração de leucócitos e/ou antagonistas da adesão do receptor de VLA-4 que pertence ao grupo das integrinas. São geralmente adequados para a terapia e a profilaxia de doenças que são causadas por uma extensão indesejada da adesão de leucócitos e/ou da migração de leucócitos ou que estão associadas com estas ou em que as interações célula-célula ou célula-matriz que estão baseadas nas interações dos receptores VLA-4 com seus ligandos desempenham uma função. A invenção, além disso, refere-se a um processo para a preparação dos compostos da fórmula (I), ao seu uso e a preparações farmacêuticas que contêm os compostos de fórmula (I).
BRPI0011296-8A 1999-05-17 2000-05-06 derivados de espiroimidazolidina, preparação dos mesmos, utilização dos mesmos e preparações farmacêuticas compreendendo os mesmos. BR0011296B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19922462A DE19922462A1 (de) 1999-05-17 1999-05-17 Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19922462.5 1999-05-17
PCT/EP2000/004090 WO2000069831A1 (en) 1999-05-17 2000-05-06 Spiroimidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them

Publications (2)

Publication Number Publication Date
BR0011296A true BR0011296A (pt) 2002-02-26
BR0011296B1 BR0011296B1 (pt) 2011-08-23

Family

ID=7908208

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0011296-8A BR0011296B1 (pt) 1999-05-17 2000-05-06 derivados de espiroimidazolidina, preparação dos mesmos, utilização dos mesmos e preparações farmacêuticas compreendendo os mesmos.

Country Status (28)

Country Link
US (1) US6399643B1 (pt)
EP (1) EP1183241B1 (pt)
JP (1) JP4686029B2 (pt)
KR (1) KR100658962B1 (pt)
CN (1) CN1221535C (pt)
AR (1) AR023989A1 (pt)
AT (1) ATE250038T1 (pt)
AU (1) AU778814B2 (pt)
BR (1) BR0011296B1 (pt)
CA (1) CA2373433C (pt)
CZ (1) CZ301467B6 (pt)
DE (2) DE19922462A1 (pt)
DK (1) DK1183241T3 (pt)
ES (1) ES2204595T3 (pt)
HK (1) HK1047104B (pt)
HU (1) HU228917B1 (pt)
IL (2) IL146276A0 (pt)
MX (1) MXPA01011611A (pt)
NO (1) NO320687B1 (pt)
NZ (1) NZ515496A (pt)
PL (1) PL201421B1 (pt)
PT (1) PT1183241E (pt)
RU (1) RU2245879C2 (pt)
SI (1) SI1183241T1 (pt)
TR (1) TR200103278T2 (pt)
TW (1) TWI256386B (pt)
WO (1) WO2000069831A1 (pt)
ZA (1) ZA200109370B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10111877A1 (de) * 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE10134366A1 (de) * 2001-07-14 2003-01-23 Aventis Pharma Gmbh Verfahren zur Herstellung der enantiomeren Formen von 2-substituierten 2-(2,5-Dioxoimidazolidin-l-yl)-essigsäure- Derivaten
DE10137595A1 (de) * 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
EP2632492B1 (en) 2010-10-25 2017-10-04 Biogen MA Inc. METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMAdCAM LEVELS

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4009506A1 (de) 1990-03-24 1991-09-26 Hoechst Ag Hydantoinderivate
DE4126277A1 (de) 1991-08-08 1993-02-11 Cassella Ag Hydantoinderivate
DK0626861T4 (da) 1992-01-13 2004-08-16 Biogen Inc Behandling af astma.
ATE151642T1 (de) 1992-02-12 1997-05-15 Biogen Inc Behandlung für entzündungserkrankung des darmes
DE4207254A1 (de) 1992-03-07 1993-09-09 Cassella Ag 4-oxo-2-thioxoimidazolidin-derivate
DE4213634A1 (de) 1992-04-24 1993-10-28 Cassella Ag 2,4-Dioxo-imidazolidin-Derivate
DE4224414A1 (de) 1992-07-24 1994-01-27 Cassella Ag Phenylimidazolidin-derivate, ihre Herstellung und ihre Verwendung
DE4228717A1 (de) 1992-08-28 1994-03-03 Cassella Ag Imidazolidin-Derivate
EP0677060A1 (en) 1993-01-08 1995-10-18 Tanabe Seiyaku Co., Ltd. Peptide inhibitors of cell adhesion
DE69419721T2 (de) 1993-01-12 2000-04-27 Biogen Inc Rekombinante anti-vla4 antikörpermoleküle
DE69407758T3 (de) 1993-02-09 2007-05-24 Biogen Idec Ma Inc., Cambridge Antikörper zur behandlung von insulinabhängigem diabetes
DE4308034A1 (de) 1993-03-13 1994-09-15 Cassella Ag Neue Heterocyclen, ihre Herstellung und ihre Verwendung
DE4427979A1 (de) 1993-11-15 1996-02-15 Cassella Ag Substituierte 5-Ring-Heterocyclen, ihre Herstellung und ihre Verwendung
WO1995015973A1 (en) 1993-12-06 1995-06-15 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
EP0804237B8 (en) 1994-01-25 2006-11-08 Elan Pharmaceuticals, Inc. Humanized antibodies against leukocyte adhesion molecule vla-4
AU2958195A (en) 1994-06-29 1996-01-25 Texas Biotechnology Corporation Process to inhibit binding of the integrin alpha 4 beta 1 to vcam-1 or fibronectin
US5811391A (en) 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
GB9524630D0 (en) 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
PT796855E (pt) 1996-03-20 2002-07-31 Hoechst Ag Inibicao da reabsorcao nos ossos e antagonistas de vitronectina
KR100504449B1 (ko) 1996-07-25 2005-07-29 바이오겐 아이덱 엠에이 인코포레이티드 세포 유착 억제제
DE19647382A1 (de) * 1996-11-15 1998-05-20 Hoechst Ag Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE19647380A1 (de) * 1996-11-15 1998-05-20 Hoechst Ag 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE19647381A1 (de) * 1996-11-15 1998-05-20 Hoechst Ag Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE19648053C1 (de) 1996-11-20 1998-03-12 Siemens Ag Elektromagnetisches Schaltgerät
WO1998042656A1 (en) 1997-03-21 1998-10-01 Cytel Corporation Novel compounds
DE19741235A1 (de) * 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) * 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
DE19821483A1 (de) * 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate

Also Published As

Publication number Publication date
KR100658962B1 (ko) 2006-12-21
CZ301467B6 (cs) 2010-03-10
JP2002544261A (ja) 2002-12-24
HK1047104B (zh) 2006-02-03
HU228917B1 (hu) 2013-06-28
NO20015617L (no) 2002-01-15
PL201421B1 (pl) 2009-04-30
KR20010113957A (ko) 2001-12-28
ATE250038T1 (de) 2003-10-15
RU2245879C2 (ru) 2005-02-10
AU4756000A (en) 2000-12-05
TWI256386B (en) 2006-06-11
DE19922462A1 (de) 2000-11-23
HUP0202364A2 (hu) 2002-11-28
EP1183241B1 (en) 2003-09-17
AU778814B2 (en) 2004-12-23
JP4686029B2 (ja) 2011-05-18
SI1183241T1 (en) 2004-02-29
IL146276A0 (en) 2002-07-25
HK1047104A1 (en) 2003-02-07
CA2373433A1 (en) 2000-11-23
CN1356986A (zh) 2002-07-03
DE60005337T2 (de) 2004-06-24
PT1183241E (pt) 2004-02-27
EP1183241A1 (en) 2002-03-06
HUP0202364A3 (en) 2003-10-28
DE60005337D1 (de) 2003-10-23
NO320687B1 (no) 2006-01-16
TR200103278T2 (tr) 2002-04-22
PL351755A1 (en) 2003-06-16
BR0011296B1 (pt) 2011-08-23
US6399643B1 (en) 2002-06-04
ZA200109370B (en) 2002-06-27
NO20015617D0 (no) 2001-11-16
IL146276A (en) 2007-06-03
MXPA01011611A (es) 2003-09-10
CA2373433C (en) 2010-12-14
CN1221535C (zh) 2005-10-05
AR023989A1 (es) 2002-09-04
WO2000069831A1 (en) 2000-11-23
ES2204595T3 (es) 2004-05-01
NZ515496A (en) 2003-10-31
CZ20014089A3 (cs) 2002-02-13
DK1183241T3 (da) 2004-01-19

Similar Documents

Publication Publication Date Title
BR9804695A (pt) Derivados de imidazolidina substituìdos, sua preparação, sua aplicação de preparações farmacêuticas contendo os mesmos
BR9705725A (pt) Heterociclos como inibidores da adesão de leucócitos e antagonistas de vla-4
BR9705727A (pt) Heterocicilos com anel de cinco membros como inibidores da adesão de leucócitos e como antigonistas de vla-4.
DE59915127D1 (de) Imidazolidinderivate, ihre herstellung, ihre verwendung und sie enthaltende pharmazeutische präparate
BR0208489A (pt) Derivados de n-(arilsulfonil) beta-aminoácidos, comportando um grupo aminoetilado substituìdo, o respectivo processo de preparação e as composições farmacêuticas que os contêm
BR9803486A (pt) Derivados de imidazolidina, sua preparação, seu uso e preparações farmacêuticas compreendendo os mesmos
MX9708781A (es) Heterociclos como inhibidores de la adhesion de leucocitos y antagonistas de vla-4.
BRPI0314325B8 (pt) derivados de aza-bicicloalquila, seu uso, seu processo de preparação e composição farmacêutica que os compreende
BRPI0411155A (pt) composto que se liga a e ativa o receptor de eritropoietina, composição farmacêutica e seu uso
BR9604895A (pt) Polioxietileno tendo um açúcar em uma extremidade e um grupo funcional diferente na outra extremidade, e um processo para a produção do mesmo
BRPI0414514A (pt) uso de um composto, composto, e, composições farmacêuticas
BR9911826A (pt) Benzimidazóis, sua preparação e seu uso como composições farmacêutica
DE60041763D1 (de) Inhibitoren von c-jun n-terminal kinasen (jnk)
YU13396A (sh) N-(3-benzofuranil) urea derivati, postupci za njihovo dobijanje, kompozicije koje ih sadrže i njihova upotreba u lekovima
BR9803969A (pt) Novos heterociclos de anel com cinco elementos, sua preparações seu uso e preparação farmacêuticas compreendendo os mesmos
FR2667068B1 (fr) Nouvelles amines alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
BR0012610A (pt) Novo derivado de difenilpiperidina
BR9916669A (pt) Uso de derivados de ácidos 4-biarilbutìricos e 5-biarilpentanóicos substituìdos como inibidores de metaloproteases de matriz para o tratamento de doenças respiratórias
BR0012478A (pt) Derivados de aminotiazóis, sua preparação e composição farmacêuticas contendo os mesmos
BR0011296A (pt) Derivados de espiroimidazolidina, preparação dos mesmos, utilização dos mesmos e preparações farmacêuticas compreendendo os mesmos
BR0316108A (pt) Derivados de fenilalquil e piridilalquil piperazina e composição farmacêutica compreendendo os mesmos
BR0207981A (pt) Derivados de imidazolidina, sua preparação, e seu uso como agente antiinflamatório
BR0316307A (pt) Compostos, processo de preparação dos mesmos, composição farmacêutica e utilização dos compostos
BR0211535A (pt) Derivados de imidazolidina, sua preparação e seu uso como antagonistas de vla-4
YU28495A (sh) Novi derivati amino kiseline postupak za njihovo pripremanje i farmaceutski preparati koji sadrže ova jedinjenja (ii)

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH (DE)

Free format text: ALTERADO DE: AVENTIS PHARMA DEUTSCHLAND GMBH

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/08/2011, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.